We carried out a "pathway" screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the 2-(acylamino)-3-thiophenecarboxylates, strongly suppressed cAMP and cGMP in multiple cell lines in response to different agonists acting on G-protein-coupled receptors, adenylyl cyclase, and guanylyl cyclase. The best compounds from structure-activity analysis of 124 analogs, including several synthesized chiral analogs, had and IC 50 of Ͻ5 M for suppression of agonist-induced cAMP and cGMP elevation.
phosphodiesterase activators, although it was not determined whether their action on phosphodiesterases is direct or indirect. The 2-(acylamino)-3-thiophenecarboxylates suppressed CFTRmediated Cl Ϫ current in T84 colonic cells in response to cholera and Escherichia coli (STa) toxins, and prevented intestinal fluid accumulation in a closed-loop mouse model of secretory diarrhea. They also prevented cyst growth in an in vitro renal epithelial cell model of polycystic kidney disease. The 2-(acylamino)-3-thiophenecarboxylates represent the first small-molecule cyclic nucleotide suppressors, whose potential therapeutic indications include secretory diarrheas, polycystic kidney disease, and growth inhibition of cAMP-dependent tumors.
Cyclic AMP (cAMP) signaling is of central importance in the regulation of cell growth, ionic composition and volume, as well as in specialized tissue functions such as transepithelial fluid secretion and absorption, and muscle contraction (Meyer et al., 2005; Murthy, 2006; van Staveren et al., 2006) . Pathological elevation in cAMP as a result of toxins, hormonal imbalance or G-protein mutations is involved in the pathogenesis of enterotoxin-mediated secretory diarrheas (Sack et al., 2004) , polycystic kidney disease (Sweeney and Avner, 2006) , and certain adenomas and other tumors (Murakami et al., 1999) . Cytoplasmic cAMP concentration is determined primarily by the rates of cAMP generation and degradation, which depend on adenylyl cyclase and phosphodiesterase (PDE) activities, respectively. The related cyclic nucleotide cGMP, which is involved in smooth muscle contraction and some types of secretory diarrheas (Vaandrager, 2002; Rybalkin et al., 2003) , is generated by guanylyl cyclase and degraded by a subset of PDEs. Drugs that increase cyclic nucleotide concentrations have proven utility in a various conditions, such as heart failure and asthma (cAMP activators) and pulmonary hypertension and erectile dysfunction (cGMP activators). In theory, drugs that reduce cyclic nucleotide concentration may be of potential utility in a different set of conditions, including secretory diarrheas, polycystic kidney disease, and tumor growth.
The original goal of this study was to identify, using a cAMP "pathway" screen, novel small-molecule inhibitors of the vasopressin-2 receptor, Gs-type G-protein, protein kinase A, and cystic fibrosis transmembrane conductance regulator (CFTR) protein. In our pathway screen, as diagrammed in Fig. 1A , activation of CFTR Cl Ϫ conductance by protein kinase A-mediated CFTR phosphorylation serves as read-out for vasopressin-induced cAMP elevation. The screen produced a novel class of vasopressin-V2 receptor (V 2 R) antagonists, as reported previously (Yangthara et al., 2007) : several CFTR inhibitors of chemical classes identified previously from a target-based screen (Ma et al., 2002; Muanprasat et al., 2004 ) and a class of 2-(acylamino)-3-thiophenecarboxylates as reported in this article. We found that the 2-(acylamino)-3-thiophenecarboxylates suppressed cellular cAMP and cGMP in different cell lines and in response to different types of agonists and seem to function as PDE activators. We optimized compound activity by synthesis and screening of structurally related analogs. The most potent analogs were characterized and shown in proof-of-concept studies to be of potential therapeutic utility in secretory diarrhea and polycystic kidney disease.
Materials and Methods
Chemicals. Forskolin, 1-desamino-8-D-arginine vasopressin (dDAVP), isoproterenol, propranolol, cholera toxin (CTX), Escherichia coli heat-stable toxin (STa), cAMP, chlorophenylthio (CPT)-cAMP, and 3-isobutyl-1-methylxanthine (IBMX) were purchased from Sigma (St. Louis, MO). Dipyridamole and MK571 were purchased from BIOMOL Research Laboratories (Plymouth Meeting, PA). Zeocin, hygromycin, and G-418 (Geneticin) were obtained from Invitrogen (Carlsbad, CA), Roche (Indianapolis, IN), and Invitrogen, respectively. Small molecules for primary screening were purchased from ChemDiv (San Diego, CA), and analogs purchased from ChemDiv and Asinex (Winston-Salem, NC). The collection of 50,000 chemically diverse, drug-like small molecules of molecular size 250 to 450 Da was screened previously (Yangthara et al., 2007) . Chemicals for synthesis were purchased from Sigma-Aldrich.
Cell Culture and Transfection. Fisher rat thyroid (FRT) cells expressing human wild-type CFTR and YFP-H148Q/I152L, with or without V 2 R, were generated as described previously (Yangthara et al., 2007) . FRT cells were cultured in F-12 modified Coon's medium (Sigma) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), 2 mM glutamine, 100 units/ml penicillin, 100 g/ml streptomycin, 500 g/ml zeocin, 350 g/ml hygromycin, and 500 g/ml G-418. CHO-K1 cells were cultured in Ham's F-12 Nutrient mix medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100 g/ml streptomycin. MDCK cells were cultured in Dulbecco's modified Eagle's medium and Earle's balanced salt solution medium supplemented with 5% fetal bovine serum, 2 mM glutamine, 0.11 mg/ml sodium pyruvate, 1.5 g/l NaHCO 3 , nonessential amino acids, 100 units/ml penicillin, and 100 g/ml streptomycin. T84 cells were maintained in Dulbecco's modified Eagle's medium/Ham's F-12 (1:1) medium containing 10% FBS, 100 units/ml penicillin, and 100 g/ml streptomycin. All cells were grown at 37°C in 5% CO 2 /95% air.
For transient transfections, CHO-K1 cells at ϳ80% confluence were transfected with cDNA encoding the hemagglutinin-tagged human ␤2-adrenergic receptor using Lipofectamine 2000 (Invitrogen) according to manufacturer's instructions. Twenty-four hours after transfection, the cells were trypsinized and plated onto a 24-well plate. Cells were used at 24 h after plating (48 h after transfection).
Fluorescence Assay for cAMP Modulators. Transfected FRT cells were plated on black 96-well plates with clear plastic bottoms (Costar; Corning Life Science, Acton, MA), cultured overnight to confluence, washed three times with PBS, and treated with test compounds in a final volume of 60 l. YFP-H148Q/I152L fluorescence was measured using a commercial plate-reader (FluoStar Optima; BMG Labtech, Winooski, VT) equipped with custom excitation and emission filters (500 nm and 544 nm, respectively; Chroma Technology Corp., Brattleboro, VT). Fluorescence in each well was measured for a total of 14 s. Two seconds after the start of data collection for each well, 100 l of PBS/I Ϫ (PBS with 100 mM Cl Ϫ replaced by I Ϫ ) was injected into the well by a syringe pump. The compound library for screening contained 50,000 chemically diverse, drug-like small molecules. Stock compounds were stored in 96-well plates at 2.5 mM in DMSO. Compounds occupied 80 wells; the remaining 16 wells contained only DMSO to be used for positive and negative controls. Screening was done using an automated apparatus (Beckman Coulter, Fullerton, CA) containing a CO 2 incubator, carousels for compound plates and pipette tip boxes, plate washer (ELx405; BioTek Instruments, Winooski, VT), liquid handling station (Biomek FX; Beckman Coulter), and plate readers (FluoStar Optima). Robotic operations were control by SAMI software (version 3.3; Beckman Coulter).
For high-throughput screening, cells expressing human wild-type V 2 R were plated in 96-well plates using a Multidrop Dispenser (Thermo Fisher Scientific). After overnight growth to reach confluence, cells were washed with PBS, and dDAVP (1 nM; Ferring Pharmaceuticals) was added together with test compounds (20 M). The first and last columns of each plate were used for positive (PBS) and negative (dDAVP; no test compound) controls. I Ϫ influx was assayed as described above after a 30-min incubation at 37°C with 95% CO 2 /5% air.
]/dt at t ϭ 0) was computed from fluorescence time course data as described previously (Muanprasat et al., 2004) . Percentage inhibition was computed as: % inhibition ϭ 100 ϫ (negative control Ϫ compound)/(negative control Ϫ positive control). Positive and negative control values denote
]/dt obtained from the first and last columns of each plate, respectively. Primary screening data were subjected to histogram analysis for "hit" selection.
Synthesis Procedures. Thin-layer chromatography was performed on Merck aluminum sheets containing silica gel 60 F 254 .
1 H NMR spectra were recorded on a 400 MHz spectrometer (Varian, Inc., Palo Alto, CA) using tetramethylsilane as internal standard. Liquid chromatography and electrospray mass spectral data were performed on an integrated liquid chromatograph/mass spectrometer (Waters, Milford, MA).
Methyl (E/Z) 2-cyano-3-tolyl-pent-2-enoate (3). Methyl cyanoacetate (0.5 g, 0.0033 mol) and 4Ј-methylpropriophenone (0.33 g, 0.0033 mol) were dissolved in dry benzene (20 ml) to which ammonium acetate (0.051 g, 0.00067 mol) and acetic acid (0.2 ml) were added. The mixture was refluxed azeotropically using a Dean-Stark apparatus until water formation ceased. The reaction mixture was cooled, dried over sodium sulfate, and concentrated in vacuo. The residue was purified by flash chromatography (silica gel, hexane: EtOAc) to afford a pale yellow oil (yield 72%).
1 H NMR (400 MHz, 
Methyl 2-amino-5-methyl-4-p-tolylthiophene-3-carboxylate (4).
A stirred solution of methyl 2-cyano-3-tolyl-pent-2-enoate (0.2 g, 0.00087 mol) in a mixture of dry THF-MeOH (10 ml) was treated with sulfur (0.033 g, 0.0010 mol) and diethylamine (0.076 g, 0.108 ml, 0.00104 mol) at ambient temperature. The reaction mixture was stirred at 35-40°C until the starting material disappeared by thinlayer chromatography. The reaction mixture was concentrated in vacuo and the residue was purified by flash chromatography to afford product 4 as a pale yellow solid (yield 68% 006 mol) was dissolved in dry THF (45 ml) and placed in a standard Parr bottle. Palladium (5%) on charcoal (ϳ 100 mg) was added and hydrogenation was carried out at 2.2 bar until H 2 uptake ceased. The catalyst was removed by filtration, the reaction mixture was concentrated under reduced pressure and petroleum ether and hexane were added to obtain product 6 as a crystalline white solid (yield 96% 
3-(3-(Methoxycarbonyl)-5-methyl-4-p-tolylthiophen-2-ylcarbamoyl)endo-bicyclo[2.2.1]heptane-2-carboxylic acid (7).
A mixture of methyl 2-amino-5-methyl-4-p-tolylthiophene-3-carboxylate and endo-bicyclo[2.2.1]heptane-2,3-dicarboxylic anhydride were heated to melting to give crude product 7. The mixture was dissolved in a minimum quantity of chloroform and crystallized in hexane/ chloroform (yield, 56-60% 
-(-(Methoxycarbonyl) -5 -methyl -4 -p-tolylthiophen-2-ylcarbamoyl)exo-bicyclo[2.2.1]heptane-2-carboxylic acid (8).
A mixture of methyl 2-amino-5-methyl-4-p-tolylthiophene-3-carboxylate and exo-bicyclo[2.2.1]heptane-2,3-dicarboxylic anhydride were heated to melting to give crude product 8. The mixture was dissolved in a minimum quantity of chloroform and precipitated with hexane (yield 56-60% until confluence (transepithelial resistance Ͼ500 ⍀ ⅐ cm). Apical membrane current was measured in an Ussing chamber (Vertical diffusion chamber; Costar) with Ringer's solution bathing the basolateral surface and half-Ringer's bathing the apical surface. The composition of Ringer's solution was: 130 mM NaCl, 2.7 mM KCl, 1.5 mM KH 2 PO 4 , 1 mM CaCl 2 , 0.5 mM MgCl 2 , 10 mM Na-HEPES, and 10 mM glucose, pH 7.3. Half-Ringer's solution was the same, except that 65 mM NaCl was replaced with Na-gluconate, and CaCl 2 was increase to 2 mM. The basolateral membrane was permeabilized with amphotericin B, as described previously (Ma et al., 2002) . Chambers were bubbled continuously with air. Apical membrane current was measured using a DVC-1000 voltage-clamp apparatus (World Precision Instruments, Inc., Sarasota, FL).
Cyclic Nucleotide Assays. Cells were grown in 24-well plates, treated with test compounds, lysed by sonication, centrifuged to remove cell debris, and assayed for cAMP or cGMP according to manufacturer's instructions (Parameter cAMP or cGMP immunoassay kit; R&D Systems).
Intestinal Fluid Secretion. Mice (CD1 strain, 25-35 g) were deprived of food for 24 h but given 5% dextrose water. After anesthesia with tribromoethanol (Avertin) 250 to 400 mg/kg i.p., generally four mid-jejunal loops (20-30 mm each) were created using suture, as described previously (Ma et al., 2002) . One hundred microliters of PBS containing CTX or STa (without or with test compound) was injected into the loops. The intestine was returned to the abdominal cavity and the incision closed with suture. The mice were allowed to recover from the surgery. Six hours later, the intestinal loops were removed, and net fluid accumulation quantified by measurement of weight-to-length ratio. Mice were euthanized by anesthetic overdose.
MDCK Cell Model of Polycystic Kidney Disease. MDCK cells were mixed with collagen (Purecol), MEM, 10 mM HEPES, pH 7.4, 100 units/ml penicillin, and 100 g/ml streptomycin, and plated at 300 cells per well in 24-well plates, as described previously (Yang et al., 2008) . After 2-h incubation in a CO 2 incubator at 37°C, cell culture media containing 1 M forskolin was added on top of the cell-containing collagen gel. The media was changed twice daily. Small cysts developed by 4 days, at which time test compounds were added and the culture continued for 7 more days. Phase-contrast light micrographs were obtained every two days using a Nikon TE 2000-S inverted microscope (Nikon Corporation, Tokyo, Japan) at 20ϫ magnification (546 nm, monochromatic illumination). Cyst growth was quantified using Image J software (http://rsbweb.nih. gov/ij/).
Results
Small-Molecule "Pathway" Screen. As diagrammed in Fig. 1A , our "pathway" screen detects increased cytoplasmic cAMP as an increase in CFTR-facilitated iodide influx, which results in fluorescence quenching of a cytoplasmic YFP-based halide sensor. A primary screen of 50,000 small molecules was done on FRT cells stably expressing human wild-type V 2 R and CFTR, and the fluorescent halide sensor YFP-H148Q/I152L. The assay was designed to identify inhibitors of the V 2 R-to-CFTR activation cascade that could target V 2 R, G s or G i proteins, adenylyl cyclase, PDE, protein kinase A, cAMP efflux pathways [multidrug-resistance proteins (MRPs)], or CFTR.
Primary screening was done with the V 2 R-selective vasopressin analog dDAVP (1 nM) and test compounds at 20 M. Figure 1B shows the kinetics of YFP fluorescence in representative wells of 96-well plates. After 2 s for collection of baseline YFP fluorescence signal, iodide addition produced a slow reduction in fluorescence in the absence of dDAVP ("positive inhibitor" control) and a rapid reduction in dDAVPtreated cells ("negative inhibitor" control). Kinetic data for various test compounds are shown, the vast majority of which were inactive (bottom three curves). Of 50,000 compounds, three compounds were identified that reduced curve slope by more than 90% after iodide addition.
Synthesis of 2-(Acylamino)-3-thiophenecarboxylates. One class of active compounds that were found to suppress cyclic nucleotide concentrations, the 2-(acylamino)-3-thiophenecarboxylates, were resynthesized and characterized for use in subsequent biological assays. Figure 2A shows structures of two comparably active close analogs identified in the primary screen. Compounds were designated CNT inh (cyclic nucleotide 
boxylic anhydride with various 5-methyl-4-substituted aryl-3-alkoxycarbonyl-2-aminothiophenes. As a representative example, the strategy for synthesis of CNT inh -03 is shown in Fig. 2B . The ␣,␤-unsaturated nitrile 3, isolated as an E/Zisomeric mixture, was obtained by heating 4Ј-methyl propiophenone and methyl cyanoacetate in benzene using a DeanStark apparatus for constant water separation in the presence of glacial acetic acid and catalytic ammonium acetate. 1 H NMR of compound 3 showed a mixture of E/Z isomers with distinct singlets at 3.84 and 3.64 ppm, corresponding to the methyl group of the methyl esters, two quartets for the methylene group, and a multiplet for the remaining methyl and aromatic protons. Knoevenagel condensation product 3 was cyclized with sulfur and diethylamine to yield 4. Condensation product 3 was converted to 4 when the reaction was carried out at 35-40°C, suggesting E-to-Z isomerization at elevated temperature. 1 H NMR confirmed a para-substituted aromatic ring, with a broad singlet of amine protons at 5.82 ppm. Three prominent singlets in the aliphatic region at 3.45, 2.34, and 2.00 ppm, corresponding to methyl ester, p-tolyl, and methyl protons, confirmed the formation of 4.
To prepare the pure individual exo and endo isomers, the (Miklos et al., 2004) . 1 H NMR of endo-and exobicyclo[2.2.1]heptane-2,3-dicarboxylic anhydride confirmed their structure, based on published data (Canonne et al., 1982) . Condensation of 4 with endo-or exo-bicyclo[2.2.1]-heptane-2,3-dicarboxylic anhydride by a melt reaction yielded endo-and exo-CNT inh -03, respectively.
Characterization and Structure-Activity Analysis of 2-(acylamino)-3-Thiophenecarboxylates. To establish structure-activity relationships, 124 synthetic analogs of CNT inh -04 were screened in the functional assay. Table 1 summarized IC 50 values for compounds of greatest interest, with data for additional active and other interesting compounds provided in the Supplemental Information. Figure 2C summarizes the structural features of the most active aryl-3-alkoxycarbonyl-2-(acylamino)thiophenes deduced from analysis of data from all compounds. The most active compounds contained p-tolyl, 3,4-dimethylphenyl, or ortho/para chlorophenyl substituents at R 4 , methyl at R 5 , methoxy or ethoxy at R 3 , and 3-bicyclo[2.2.1]heptyl-2-carboxylic acid at R 2 of the thiophene nucleus. It is noteworthy that the endo-and exostereoisomers showed comparable potencies. As tabulated in Supplemental Information, the bicycloheptyl ring system at position R 2 could be substituted for various other nonaromatic multicyclic ring systems. Activity was abolished or substantially reduced with other substitutions at R 2 , including N,Ndimethylaminomethyl, methyl, chloromethyl, 2-carboxyphenyl, mono-, di-, and trisubstituted nitrophenyl, substituted methoxyphenyl, 3-chlorobenzthiophenyl, pyridine-3-yl, coumaryl, tetrahydrofuryl, 1,4-benzodioxyl, substituted carboxy cyclohexenyl, substituted halophenyl, thiophene-2-yl, isoindolinyl-1,3-dione, anilino, and furanyl. Figure 2D shows inhibition by CNT inh -03 of chloride conductance (left) and cellular cAMP (right) in the V 2 R and CFTR-expressing FRT cells used for primary screening. By short-circuit current analysis, the apparent IC 50 for inhibition of CFTR chloride current after dDAVP stimulation was ϳ6 M. Cellular cAMP was reduced to near zero with increasing CNT inh -03. The reduced cytoplasmic cAMP concentration provides evidence against protein kinase A or CFTR as principle targets of CNT inh -03.
Target Identification. Experiments were done to identify the cellular target of the 2-(acylamino)-3-thiophenecarboxylates. Figure 3A , left, shows that CNT inh -03 was as effective as propranolol in reducing cAMP after isoproterenol stimulation in cells expressing ␤2-adrenergic receptors. Reduced cAMP was also found in CHO-K1 cells after forskolin or cholera toxin (Fig. 3A, middle and right) . Reduced cAMP was also seen in various other cell lines (FRT, MDCK, T84) after agonist stimulation (data not shown). These results suggest the target of 2-(acylamino)-3-thiophenecarboxylate action is downstream of receptors and adenylyl cyclase, possibly by direct or indirect action on PDE(s). In support of action on PDEs was the finding that the 2-(acylamino)-3-thiophenecarboxylate suppressed cGMP levels in different cell types, as demonstrated in Fig. 3B in T84 cells after stimulation by STa toxin. Additional evidence supporting an action on PDEs was the finding that the nonselective PDE inhibitor IBMX (at 100 M) partially abrogated the 2-(acylamino)-3-thiophenecarboxylate effect on cAMP suppression, as shown in several cell types such as CHO-K1 cells (Fig. 3C) .
To test directly whether the 2-(acylamino)-3-thiophenecarboxylates act as PDE activators, short-circuit current measurements were done on CFTR-expressing FRT cells after permeabilization of the basolateral membrane and application to the basolateral bathing solution of low concentrations of cAMP or the relatively hydrolysis-resistant cAMP analog CPT-cAMP. Figure 3D shows stimulation of CFTR chloride current with added cAMP or CPT-cAMP (top and third curves). However, after pretreatment with CNT inh -03, the increase in chloride current after cAMP was greatly reduced (second curve), whereas that after CPT-cAMP was not affected (fourth curve). These results provide evidence for in- at ASPET Journals on July 6, 2017 molpharm.aspetjournals.org
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volvement of cAMP hydrolysis in compound action, suggesting direct or indirect action on PDEs. One other possibility was considered as the target of CNT inh -03 action-increased cellular cAMP efflux via plasma membrane pumps such as multidrug-resistance (MRP) proteins Li et al., 2007) . Evidence against this possibility is the generality of cAMP and cGMP suppression in multiple cell types. Furthermore, Fig. 3E shows that an inhibitor of MRP-mediated cAMP efflux, dipyridamole , did not affect CNT inh -03 action. The lack of direct effect of dipyridamole on chloride current indicates that dipyridamole does not activate PDEs under the conditions of our experiments. Similar results showing no effect on CNT inh -03 action were found for a different inhibitor of cAMP efflux, MK571 (20 M) (data not shown).
Compound Efficacy in Models of Secretory Diarrhea and Polycystic Kidney Disease. As mentioned in the Introduction, there are several potential clinical applications of agents that reduce cyclic nucleotide concentration. Fluid secretion into the intestinal lumen in enterotoxin-mediated secretory diarrheas is produced by increased concentration of cyclic nucleotides in enterocytes, examples of which include cholera toxin causing elevated cAMP in cholera and STa toxin causing elevated cGMP in Traveler's (enteropathogenic E. coli) diarrhea (Field, 2003) . Elevated cyclic nucleotide concentration activates CFTR, resulting in transcellular chloride secretion across the intestinal epithelium, which is followed by sodium and water secretion. T84 colonic epithelial cells are a commonly used human intestinal cell model of chloride secretion (Barrett, 1993) . Figure 4A , left, shows slow activation of CFTR in T84 cells after cholera toxin. Shortcircuit current was fully inhibited by CNT inh -03. Figure 4A (right) shows an even greater potency of CNT inh -03 for inhibition of short-circuit current after stimulation by STa toxin. These results are consistent with the data above showing reduced cAMP and cGMP concentrations in different cell types and with different agonists.
T84 cells develop large intracellular vacuoles at 3 h after cholera toxin exposure (Barkla et al., 1992; Crane et al., 2006) , as shown in Fig. 4B . This change in morphology is thought to be caused by cAMP-dependent (though CFTRindependent) fluid secretion into intracellular vesicles. Figure 4B shows that CNT inh -03 largely prevents the cholera toxin-induced vacuolarization in T84 cells, whereas CFTR chloride channel inhibition by CFTR inh -172 does not.
We tested the efficacy of CNT inh -03 in reducing intestinal fluid accumulation in a well established closed-loop mouse model of secretory diarrhea used extensively by our lab to evaluate the antisecretory properties of CFTR inhibitors (Thiagarajah et al., 2004) . Intestinal loops were injected with saline, cholera toxin, or STa toxin, with or without CNT inh -03. Intestinal loop fluid accumulation was quantified by loop weight-to-length ratio at 6 h. Figure 4C , left, shows that loop fluid accumulation increased greatly after cholera toxin and that the fluid accumulation was partially inhibited by CNT inh -03. Figure 4C , middle, shows significant though lower stimulation of loop fluid accumulation by STa toxin compared with cholera toxin. CNT inh -03 fully inhibited loop fluid accumulation after STa toxin. Figure 4C , right, shows that CNT inh -03 did not affect intestinal fluid absorption, which is an important requirement for its potential application as an antidiarrheal.
Long-term elevation of cAMP in epithelial cells lining renal cysts is thought to be responsible for progressive cyst expansion in autosomal dominant polycystic kidney disease by stimulating epithelial cell proliferation and CFTR-dependent fluid transport into the cyst lumen (Mangoo-Karim et al., 1989) . We used an established MDCK model of in vitro cyst formation (Yang et al., 2008) to test whether the 2-(acylamino)-3-thiophenecarboxylates could inhibit cyst growth. Figure 5A shows representative photographs of MDCK cell cysts over time after plating in a Matrigel matrix in the presence of forskolin. CNT inh -03 remarkably reduced cyst expansion. Data from many individual cultures are summarized in Fig.  5B , as the ratio of final-to-initial cyst area. Although consid- 
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at ASPET Journals on July 6, 2017 molpharm.aspetjournals.org erable heterogeneity in cyst areas was seen, CNT inh -03 clearly prevented the growth of large cysts. Figure 5C , left, summarizes the data as the percentage of total number of MDCK cells that formed cysts, as defined as structures with diameter Ͼ100 m and having a lumen. CNT inh -03 significantly reduced the percentage of MDCK cells that progress to form cysts. Figure 5C , right, confirmed that cAMP concentration was suppressed in forskolin-treated MDCK cells under the conditions of the cyst formation studies.
Discussion
The 2-(acylamino)-3-thiophenecarboxylates identified here are to our knowledge the first small-molecule general suppressors of cellular cyclic nucleotides. They reduced basal and agonist-induced elevation in cytoplasmic cAMP and cGMP concentrations in multiple cell types and in response to different types of agonists. Their mechanism of action seems to involve nonselective activation of PDEs, although we did not investigate whether they act direct or indirectly on PDEs. The compounds discovered here should be useful research tools in probing cyclic nucleotide signaling mechanisms, and notwithstanding specificity concerns, potentially for therapy of secretory diarrheas, polycystic kidney disease, and cAMP-dependent tumor growth. The strong PDE5/cGMP activating potency of 2-(acylamino)-3-thiophenecarboxylates also suggests their utility in preventing nitric oxide/cGMPinduced vasodilation, as in acutely antagonizing the actions of sildenafil or related PDE5 inhibitors.
Several lines of evidence suggested that the 2-(acylamino)-3-thiophenecarboxylates target PDEs. Both cAMP and cGMP were reduced in different cell types and in response to different agonists, including G protein-coupled receptor agonists, forskolin, CTX, and STa toxin. The 2-(acylamino)-3-thiophenecarboxylates abolished downstream cAMP action in response to added cAMP in permeabilized cells but not to the relatively hydrolysis-resistant analog CPT-cAMP. These and related experiments excluded a primary action of the compounds on GPCRs, G-proteins, adenylyl cyclase, protein kinase A, cyclic nucleotide cellular efflux, and CFTR. Further studies are needed to define compound selectivity to different PDE isoforms and the site of putative compound-PDE interaction. Such studies may present a considerable challenge because there are at least 11 PDE isoforms with extensive redundancy, cross-talk, and positive and negative feedback mechanisms and because the functions of several PDE isoforms remain incompletely understood (Bender and Beavo, 2006; Omori and Kotera, 2007) . Further studies are also needed to determine whether compound action on PDEs is direct or indirect, perhaps acting though various kinases and/or phosphatases that modulate PDE activity.
Retrosynthetic analysis of CNT inh -03 and CNT inh -04 revealed the two important synthons as bicyclo[2.2.1]heptane-2,3-dicarboxylic anhydride (compounds 5 and 6) and 5-methyl-4-substituted aryl-3-alkoxycarbonyl-2-aminothiophene (compound 4). The Gewald synthesis is the most versatile method for the synthesis of the key synthon 5-methyl-4-substituted aryl-3-alkoxycarbonyl-2-aminothiophene, 4, which was generated by a two-step procedure involving isolation of the ␣,␤-unsaturated nitrile, 3, from the Knoevenagel condensation of 1 and 2. Subsequent conversion of the olefin, 3, to the corresponding 2-aminothiophene, 4, was accomplished by treatment with sulfur and diethylamine. Condensation of 3-methoxycarbonyl-5-methyl-4-p-toyly-2-aminothiophene, 4, with endo-or exo-bicyclo[2.2.1]heptane-2,3-dicarboxylic anhydride (compounds 5 and 6) gave the endo and exo isomers of 3-methoxycarbonyl-5-methyl-4-p-toyly-2-aminothiophene bicyclo[2.2.1]heptane-2-carboxylic acid (compounds 7 and 8). Structure-activity analysis of 124 analogs indicated 4-substituted aryl-3-alkoxycarbonyl-thiophen-2-ylcarbamoyl bicyclo[2.2.1]heptane-2-carboxylic acids as most potent cyclic nucleotide suppressors. It is noteworthy that we found little stereo-specificity in compound activity, allowing replacement, with minimal loss of function, of the bicycloheptane moiety with various other multicyclic moieties.
Proof-of-concept experiments support the potential utility of 2-(acylamino)-3-thiophenecarboxylates in reducing intestinal fluid accumulation in secretory diarrheas and slowing renal cyst growth and fluid accumulation in polycystic kidney disease. In response to cholera and STa toxins, the 2-(acylamino)-3-thiophenecarboxylates inhibited short-circuit current in T84 cells, a commonly used model of intestinal chloride secretion. In vivo, the 2-(acylamino)-3-thiophenecarboxylates reduced fluid accumulation in closed intestinal loops in mice at 6 h during continuous toxin exposure. PDE activation represents a novel strategy to reduce intestinal fluid secretion, which adds to the list of antisecretory mechanisms in clinical development, including CFTR and encephalinase inhibitors (reviewed in Thiagarajah and Verkman, 2005) . The 2-(acylamino)-3-thiophenecarboxylates also slowed cyst growth and fluid accumulation in an in vitro MDCK model of polycystic kidney disease. Other antisecretory strategies under consideration for reducing fluid influx into renal cysts in polycystic kidney diseases include V 2 R antagonism (Torres, 2008) and CFTR inhibition (Yang et al., 2008) . Small-molecule PDE activators thus provide an alternative to therapies under development for secretory diarrheas and polycystic kidney disease.
In conclusion, the 2-(acylamino)-3-thiophenecarboxylates identified here, which seem to function as nonselective PDE activators, permit pharmacological suppression of cyclic nucleotides in cells and tissues. Potential applications of this compound class in reducing intestinal fluid secretion and renal cell cyst expansion were demonstrated. However, because PDEs are ubiquitously expressed, considerable further development is needed to achieve PDE isoform selectivity and selective organ/cell targeting. 
